Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
基本信息
- 批准号:10116259
- 负责人:
- 金额:$ 19.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAgingAllogenicAntigensAutoantigensAutoimmune DiseasesBlood CirculationCellsCessation of lifeDataDevelopmentDropsEndocrineEnsureFailureFetal ViabilityFetusFoundationsGenerationsGoalsHormonesHumanImmuneImmune ToleranceImmune responseImmune systemImmunityIndividualInfiltrationKnowledgeLeadLeukocytesLocationMalignant NeoplasmsMaternal-Fetal ExchangeMaternally-Acquired ImmunityMediatingMedicineModelingMusNursesOperative Surgical ProceduresOrgan TransplantationOutcomeOutputPeripheralPhysiologicalPre-EclampsiaPregnancyPregnancy OutcomePregnant WomenPremature BirthPreventionPrevention strategyProductionProgesteroneProgesterone ReceptorsRegulationRegulatory T-LymphocyteReporterReproductive systemResearchRoleSiteSpontaneous abortionStructureT-Cell DevelopmentT-LymphocyteTestingTherapeuticThymic epithelial cellThymus GlandTimeTransplantationWomanWorkadverse pregnancy outcomebasecancer cellearly pregnancyexperimental studyfetalfetal losshealthy pregnancyimprovedin vivoin vivo Modelinsightmouse modelnovelperipheral bloodpregnancy disorderpreventreceptor expressionresponsesteroid hormonesuccesstherapeutic development
项目摘要
Elucidation of mechanisms whereby maternal immune tolerance to the semi-allogeneic fetus is established will yield important insight for development of novel preventative and therapeutic strategies to ensure healthy pregnancies. During pregnancy, progesterone has dramatic effects on the maternal thymus, the location wherein all T cells develop. Using a newly developed murine model, we have found that progesterone action in the thymus is required for optimal pregnancy outcome. Further, we found that the thymus responds early in pregnancy, during the time at which maternal tolerance to the fetus is established. Since the thymus is critical for generating regulatory T cells, which are key for successful pregnancy, our data lead us to hypothesize that pregnancy induces early changes to promote generation of thymus-derived regulatory T cells that in turn confer maternal-fetal tolerance. To address this postulate, we use our novel in vivo model to test the role of progesterone and pregnancy on thymic function and maternal-fetal tolerance in two Specific Aims: AIM 1. Determine the effects of pregnancy and PR in thymic epithelial cells on the dynamics of regulatory T cell production by the thymus. AIM 2. Determine the role of PR in thymic epithelial cells on fetal survival in allogeneic pregnancies and on functionality of TReg in pregnancy. The studies proposed here will overcome our limited understanding of a long-documented, but poorly understood phenomenon in pregnancy. Further, elucidation of the mechanisms of maternal-fetal tolerance, including the role of steroid hormones, have implications extending well beyond pregnancy, and will help to lay foundations for new ways to target and kill cancer cells, improve transplantation outcome, bolster the aging immune system, and prevent autoimmune disease.
阐明母体对半同种异体胎儿的免疫耐受机制将为开发新的预防和治疗策略以确保健康妊娠提供重要的见解。在怀孕期间,孕酮对母体胸腺有显著的影响,胸腺是所有T细胞发育的地方。使用一个新开发的小鼠模型,我们发现,孕激素的作用,在胸腺所需的最佳妊娠结局。此外,我们还发现胸腺在妊娠早期即母体对胎儿耐受性建立期间有反应。由于胸腺对于产生调节性T细胞至关重要,而调节性T细胞是成功妊娠的关键,因此我们的数据使我们假设妊娠诱导早期变化以促进胸腺衍生的调节性T细胞的产生,从而赋予母胎耐受性。为了解决这一假设,我们使用我们的新的体内模型来测试孕激素和妊娠对胸腺功能和母胎耐受的作用,在两个特定的目的:AIM 1。确定妊娠和胸腺上皮细胞PR对胸腺产生调节性T细胞动力学的影响。AIM 2.确定胸腺上皮细胞中PR对同种异体妊娠中胎儿存活和妊娠中TReg功能的作用。这里提出的研究将克服我们对长期记录但知之甚少的怀孕现象的有限理解。此外,对母胎耐受机制的阐明,包括类固醇激素的作用,具有远远超出妊娠的影响,并将有助于为靶向和杀死癌细胞的新方法奠定基础,改善移植结果,支持衰老的免疫系统,并预防自身免疫性疾病。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET G PETROFF其他文献
MARGARET G PETROFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET G PETROFF', 18)}}的其他基金
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
- 批准号:
10396646 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
- 批准号:
10215585 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
- 批准号:
9979498 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
- 批准号:
10617856 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Shared Placenta/Tumor Antigens and Maternal Immunity
共享胎盘/肿瘤抗原和母体免疫
- 批准号:
9316903 - 财政年份:2017
- 资助金额:
$ 19.56万 - 项目类别:
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
人类妊娠期对 HCV 的先天性和适应性免疫
- 批准号:
8654226 - 财政年份:2014
- 资助金额:
$ 19.56万 - 项目类别:
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
人类妊娠期对 HCV 的先天性和适应性免疫
- 批准号:
9021550 - 财政年份:2014
- 资助金额:
$ 19.56万 - 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
- 批准号:
8038448 - 财政年份:2010
- 资助金额:
$ 19.56万 - 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
- 批准号:
7774089 - 财政年份:2010
- 资助金额:
$ 19.56万 - 项目类别:
FUNCTIONAL COOPERATION BETWEEN TROPHOBLAST HLA-G AND B7 FAMILY
滋养层 HLA-G 和 B7 家族之间的功能合作
- 批准号:
7699715 - 财政年份:2008
- 资助金额:
$ 19.56万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 19.56万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 19.56万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 19.56万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 19.56万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 19.56万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 19.56万 - 项目类别: